FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

	OMB APPROVAL										
0	OMB Number: 3235-02										
E:	Estimated average burden										
ho	ours per response	. 0.5									

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person* Panzara Michael A.						2. Issuer Name and Ticker or Trading Symbol Wave Life Sciences Ltd. [WVE]								(Checl	k all app Direc	licable)	ng Person(s) to Is 10% O Other (wner
(Last) (First) (Middle) C/O WAVE LIFE SCIENCES LTD.,					3. Date of Earliest Transaction (Month/Day/Year) 02/16/2022								X	belov	See Remark		below)		
733 CONCORD AVE. (Street) CAMBRIDGE MA 02138 (City) (State) (Zip)						4. If Amendment, Date of Original Filed (Month/Day/Year)							6. Indi Line) X	, ·					
		Table	I - No	n-Deriva	tive S	Secu	rities	Acq	uired	, Dis	posed of	, or E	Benefi	cially	Own	ed			
1. Title of Security (Instr. 3) 2. Transacti Date (Month/Day)					Execution Date,		3. 4. Securities Acquir Transaction Disposed Of (D) (Ins Code (Instr. 8)					5. Amount of Securities Beneficially Owned Following Reported		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)		7. Nature of Indirect Beneficial Ownership (Instr. 4)			
									Code	v	Amount	(A) ((D)	or Pri	се	Transa	ction(s) 3 and 4)			(
Ordinary Shares 02/16/20					022			S ⁽¹⁾		10,603	D	\$2	31 ⁽²⁾	7:	5,817	D			
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)																			
1. Title of Derivative Security (Instr. 3)	f e Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3. Deemed Execution Date, if any (Month/Day/Year)		4. Transaction Code (Instr. 8)		of Deriv Secu Acqu (A) o Dispo	r osed) r. 3, 4	Expiration Day/\(\)		ate Amo Year) Secu Undo Deriv Secu		7. Title and Amount of Securities Underlying Derivative Security (Instr 3 and 4)		Price of rivative curity str. 5)	9. Number derivative Securities Beneficial Owned Following Reported Transaction (Instr. 4)	Ownersl Form: y Direct (I or Indire (I) (Instr.	nership m: ect (D) ndirect	Beneficial Ownership ct (Instr. 4)		
					Code	v	(A)	(D)	Date Exercis	able	Expiration Date	Title	Number of Shares						

Explanation of Responses:

- 1. On February 16, 2022, the reporting person sold 10,603 ordinary shares solely to cover taxes associated with the vesting of restricted share units ("RSUs") on February 15, 2022. These sales were made pursuant to a provision in the reporting person's RSU agreement that requires automatic sales of shares to cover tax withholding obligations.
- 2. The price reflected is the weighted-average sale price for shares sold. The shares were sold in multiple transactions and the range of sale prices for the transactions reported was \$2.31 to \$2.38 per share. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price.

Chief Medical Officer, Head of Therapeutics Discovery and Development

/s/ Michael A. Panzara 02/18/2022

** Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.